Quick answers
- What is Zarontin?
- Zarontin is a brand name of Ethosuximide, a prescription medicine. The FDA NDC Directory lists 2 Zarontin products in 2 strengths and forms.
- Who makes Zarontin?
- Parke-Davis holds the FDA application for Zarontin (NDA012380, approved November 2, 1960).
- Is there a generic or store brand of Zarontin?
- Yes. The FDA NDC Directory lists 8 other products with the same active ingredients, strength and form as a Zarontin product, 8 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Zarontin?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Zarontin strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Zarontin been recalled?
- FDA enforcement reports list 1 recall of Zarontin products; the newest started September 12, 2019. A recall usually concerns specific lots, not every product.
What Zarontin is
Each Zarontin product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Ethosuximide · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| ethosuximide 250 mg capsule (oral) | Zarontin | 4 products, 3 companies | DailyMed |
| ethosuximide 250 mg/5 mL solution (oral) | Zarontin | 4 products, 4 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ethosuximide →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA012380 | Parke Davis | November 2, 1960 | 1 |
| ANDA080258 | Parke-Davis | February 13, 1974 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ethosuximide 250 mg capsule | Brand: Zarontin | $1.31 per capsule Generic of the same strength and form: $0.2623 per capsule |
NADAC list of November 4, 2026; these prices took effect on January 1, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Zarontin
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Zarontin products.
- Parke-Davis Div of Pfizer Inc2 products
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
September 12, 2019 · Class III · Terminated · D-0002-2020
Labeling: Incorrect or Missing Lot and/or Exp Date. The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.
Zarontin (ethosuximide capsules, USP) 250 mg, 100-count bottle, Rx Onl,y Made in Netherlands Distributed by Parke-Davis Division of Pfizer In NY, NY 10017, NDC 0071-0237-24 — Pfizer Inc.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.